alexa Renal Cell Carcinoma in Kindey Allografts: Case Report Series and Review of the Literature | OMICS International
ISSN: 2161-0959
Journal of Nephrology & Therapeutics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Renal Cell Carcinoma in Kindey Allografts: Case Report Series and Review of the Literature

Sayed Husain*, Felix Perez, Rada Gerbi, Mariella Goggins, Anita Patel and Venkat KK

Department of Nephrology & Hypertension, Henry Ford hospital, Wayne State university, USA

*Corresponding Author:
Sayed Husain
Department of Nephrology & Hypertension
Henry Ford Hospital, Wayne State University, USA
E-mail: [email protected]

Received Date: March 12, 2013; Accepted Date: July 18, 2013; Published Date: July 22, 2013

Citation: Husain S, Perez F, Gerbi R, Goggins M, Patel A, et al. (2013) Renal Cell Carcinoma in Kindey Allografts: Case Report Series and Review of the Literature. J Nephrol Ther 3:132. doi:10.4172/2161-0959.1000132

Copyright: © 2013 Husain S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nephrology & Therapeutics

Abstract

The overall incidence of malignancy after renal transplantation is three to five times higher than in general population. As a result malignancy is the third most common cause of death in renal recipients. Three cases are given below of de novo renal allograft tumor occurring after transplantation. Case 1 is about a 57-year old female patient who underwent kidney transplant (LRKT) with zero haplotype match from her cousin and the case 2 discuss about a 45-year old female who developed ESRD secondary to chronic glomerulonephritis v/s hypertensive sclerosis. Last case report discusses about 46-year old Caucasian male with a history of Ig A and Granulomatosis with polyangiitis received LRKT from his brother.

Introduction

The overall incidence of malignancy after renal transplantation is three to five times higher than in general population. As a result malignancy is the third most common cause of death in renal recipients [1]. Non melanoma skin cancer (NMSC) and lymphoma are the most common malignancies followed by renal cell carcinoma (RCC) [1]. The classic triad of hematuria, abdominal pain and flank pain is not a feature of RCC transplant. The median time lapse between transplantation and tumor diagnosis is between 3 and 19 years or longer as reported in literature. Most of the RCC are found in the recipient’s native kidneys and only few cases of RCCs in renal allograft have been reported so far. As a result allograft tumor is an unusual and rare complication. Obesity, analgesic abuse, tobacco, repeated pyelonephritis along with immunosuppression is the risk factors facilitating the development of allograft and native RCC [2]. Israel Penn Transplant Tumor Registry has reported only 45 cases of allograft RCC [3]. Genetic analysis and immunologic human leukocyte antigen typing should be assessed on the basis of tumor specimen to identify the donor or recipient origin of RCC. Treatment options for these cancers include radiofrequency ablation and partial or total nephrectomy, depending on the patient’s performance status and staging of the RCC. Three cases are given below of de novo renal allograft tumor occurring after transplantation.

Case Reports

Case 1

A 57-year old Hispanic female with a history of HTN and End Stage Renal Disease (ESRD) secondary to Systemic lupus Nephritis (SLE) in December 1994, underwent living related kidney transplant (LRKT) with zero haplotype match from her cousin. She had a baseline creatinine of 0.9-1.1 mg/dl. There was no history of malignancies in her family. She was placed on Imuran, Cyclosporine (CSA) and steroids. Due to steroid induced complications her Imuran was discontinued and Cellcept was started and steroids were tapered. In 2008, she had a CT of abdomen due to abdominal pain and a 10 mm enhancing mass in left native kidney was discovered. Interventional radiology (IR) guided biopsy was performed which was inconclusive and showed no discrete mass lesion with deeper cuts. The mass was later treated with cryoablation. Follow up MRI was performed in November 2011, which showed 1.3 cm × 1.3 cm mass in the lower pole of the right allograft but no changes were noted in the prior ablation site of the left native kidney. CSA was switched to Rapamune. A repeat biopsy showed Conventional Clear type tumor- Grade1 and as result required allograft nephrectomy and was started on hemodialysis (HD). Left native nephrectomy was planned due to suspicion for being the primary source. Unfortunately, her donor was also diagnosed with RCC (Figure 1).

nephrology-therapeutics-biopsy-report-case

Figure 1: Biopsy Report Case#1.

Case 2

A 45-year old African American female with a history of coronary artery disease with stent, hypertension during pregnancy and proteinuria as a teenager developed ESRD secondary to chronic glomerulonephritis v/s hypertensive sclerosis. Patient had no family history of any malignancies. Initially, hemodialysis was started in October 1997, for about 3 years. Later, she underwent an LRKT from her sister with one haplotype match in July 2001. Her transplant was complicated with severe cellular rejection with necrotizing arteriolitis and thrombosis, and treated with Thymoglobulin, OKT3 and plasmapheresis. She later maintained good graft function with creatinine in the range of 1.5- 1.6mg/dl.on steroids, Cellcept, Prograf and Rapamune. In 2003, her immunosuppressants (IS) were changed to Cellcept and Cyclosporine due to toxicities. Subsequent rejection occurred in 2010 and required intravenous steroids. She developed chronic intermittent microscopic hematuria which led to an Ultrasound (U/S) finding of 1.8 cm hypo echoic lesion on the lateral aspect of the graft in 2010. Due to unknown cardiac stent MRI was not performed. Urological workup showed normal cystoscopy and cytology. However, subsequent ultrasounds within 4-5 months showed a complex cyst of 1 × 1.2 cm along with the mass which had regressed to 1.3 cm. Radiology raised suspicion for post transplant lymphoproliferative disorder (PTLD), which requires biopsy of the graft showing papillary renal cell carcinoma with potential mulitfocality of the lesion. As a result, transplant nephrectomy of the right kidney was performed on September 2011. Her current status is that she is on hemodialysis but the status of the donor is unknown (Figure 2).

nephrology-therapeutics-biopsy-case

Figure 2: Biopsy Case#2.

Case 3

A 46-year old Caucasian male with a history of Ig A and Granulomatosis with polyangiitis (Wegener’s, GPA) received LRKT from his brother in 1997, which was performed at the University of Michigan. GPA was treated with Cyclophosphamide, Cellcept and prednisone. Post transplant, he was administered with cyclosporine and Cellcept. His graft function was stable for the last 14 years with creatinine around 1.9-2.2 mg/dl. He visited the institute due to failing kidney function as his creatinine level increased from baseline 2.26 mg/dl to 6.8 mg/dl. His U/S and CT scan were indicative of a solid and vascular lesion of 3.1×3.3×3.6 cm which was a complex cyst in the anterior aspect of the left allograft suspicious for PTLD v/s RCC. In the interim he was started on HD. Urology was consulted for a-typical cytology of the urine. Cystoscopy was performed and found to be normal; as a result, fluorescent in situ hybridization (FISH) was performed. He underwent transplant nephrectomy in September 2011, and biopsy was performed on the same day showing papillary renal carcinoma (Figure 3 and Table 1).

nephrology-therapeutics-biopsy-case

Figure 3: Biopsy Case#3.

Age/Sex Primary Disease HD IS Tumor Location/Size Type Donor
57/F SLE - Cyclosporine-Cellcept-Rapamune-Prednisone RK/1.3 cm Clear Cell Grade-1 LRKT/Cousin Zero Haplotype
45/F GN? 36 m Cellcept -Cyclosporine RK/1.3 cm Papillary Cell Grade-3 LRKT/Sister One Haplotype
46/M GPA - Cyclosporine -Cellcept LK/3.1 cm Papillary Cell Grade-3 LRKT/Brother

Table 1: The Clinical and Pathological Characteristics of the Patients.

Discussion

Papillary carcinoma is the second most common frequent carcinoma observed in 10-15% cases of RCCs. it is also common in dialysis and transplant patients due to immunosuppression and dialysis related factors [4]. Trisomies of 3q, 7, 12, 16, 17, 20 and loss of Y chromosome are the frequent genetic abnormalities in papillary subset. Conventional clear cell carcinoma is the most common cancer of the renal tubular epithelium and is associated with abnormality of chromosome 3p6. Two of the three patients in this case report had papillary origin. The uniqueness of this case series is that all of the RCC in allograft were found to be from live donors and occurred after a span of many years. Allograft tumor cases have been reported sporadically in the transplant literature. The cause most of these cases have been due to deceased donor and origin of these tumor cells is from a donor kidney or secondary to a metastatic implant from a primary tumor of the recipient. Therefore, it is recommended to perform genetic studies to differentiate between donors versus recipient origin. In a few RCC cases, genetic studies by using fluorescence in situ hybridization (FISH) analysis have confirmed the origin of the tumor cells to be the donor kidney. Duplication and activation of MET proto-oncogene on chromosome 7q have been observed in familial and sporadic cases of papillary RCC. Interestingly, monosomy 7 and 17 was discovered by FISH in significant proportion of these tumor cells [5-7]. DNA microsatellite, which is short repetitive DNA sequences polymorphic in length and scattered throughout genome, can be analyzed and have proven to be beneficial in a case report to diagnose recipient cell origin in the grafted kidney [8]. Also, studies have shown that origin of allograft tumor is attributed to bone marrow derived cells migrating to kidney after AKI [9] or stem cells from kidney transformed to produce malignancy [10-12]. In the given cases it was difficult to perform genetic work prior to transplantation as the living donors and recipients suggested minimal risk factors for RCC such as analgesic abuse, tobacco use, cystic diseases, BK virus or dialysis. Even though a long-term follow up is not yet available but the clinical and radiological follow ups of the donors have not shown any signs of malignancy. This suggests the possibility that donor kidney harbored tumor at the time of transplantation which remained undiagnosed. However, the possibility of some genetic predisposition may be responsible to cause RCC in an allograft rather than native kidney. This could lead to malignant transformation of the cells of the graft along with low possibility of the unnoticed transplanted tumor.

Since these tumors are quite rare, therefore, no general consensus or guidelines have been implicated on the management of these patients. Although partial graft nephrectomy less than 4 cm in diameter is encouraged by Ribal et al. [13] and Chambade et al. [14] with the advantage of preserving graft function and reducing the need to start HD again which is associated with poor survival [14]. However, surgical expertise is required as coexistence of renal and peri renal inflammations make it difficult to maneuver the parenchyma. As a result, risk of hemorrhage and urinoma and even secondary total nephrectomy is high with open or laparoscopic partial or radical nephrectomy.

Another approach is to perform percutaneous thermal ablation. This minimally invasive option leads to preservation of graft function and low morbidity. A recent multicenter retrospective analysis showed that precutaneuos ablation is a safe and effective approach in treating de novo RCC in renal transplant [15]. This retrospective analysis has identified 24 tumors in 20 patients with maximal diameter of masses between 6-40 mm, treated mostly with radiofrequency ablation or with cryoablation. This technique has proved to be beneficial as only one patient had a new tumor in a different location after 2 years of follow up and in some cases multifocal RCC were also treated. In those cases where there was complex nature of the lesions and suspicion of the multifocality of the lesion, so transplant nephrectomy was preferred.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • World Nephrologists Meeting
    July 23-24, 2018 Kuala Lumpur, Malaysia
  • 22nd European Nephrology Conference
    October 15-16, 2018 Warsaw, Poland
  • 18th International Conference on Nephrology & Therapeutics
    October 22-23, 2018 Osaka, Japan

Article Usage

  • Total views: 11814
  • [From(publication date):
    July-2013 - Jul 23, 2018]
  • Breakdown by view type
  • HTML page views : 8040
  • PDF downloads : 3774
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7